See more : Oxford Instruments plc (OXIG.L) Income Statement Analysis – Financial Results
Complete financial analysis of Solid Biosciences Inc. (SLDB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Solid Biosciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tokio Marine Holdings, Inc. (TKOMF) Income Statement Analysis – Financial Results
- American Scientific Resources, Incorporated (ASFX) Income Statement Analysis – Financial Results
- YeaShin International Development Co., Ltd. (5213.TWO) Income Statement Analysis – Financial Results
- 808 Renewable Energy Corporation (RNWR) Income Statement Analysis – Financial Results
- Ankit Metal & Power Limited (ANKITMETAL.BO) Income Statement Analysis – Financial Results
Solid Biosciences Inc. (SLDB)
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 8.09M | 13.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 76.56M | 2.41M | 58.74M | 3.92M | 2.82M | 1.57M | 448.00K | 56.00K | 0.00 |
| Gross Profit | -76.56M | 5.69M | -45.12M | -3.92M | -2.82M | -1.57M | -448.00K | -56.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 70.25% | -331.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 76.56M | 78.42M | 58.74M | 64.88M | 94.74M | 57.97M | 39.91M | 20.12M | 4.19M |
| General & Administrative | 27.75M | 28.95M | 27.14M | 21.58M | 24.58M | 17.72M | 14.95M | 5.46M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.75M | 28.95M | 27.14M | 21.58M | 24.58M | 17.72M | 14.95M | 5.46M | 2.37M |
| Other Expenses | 0.00 | -381.00K | 2.00K | 1.94M | 515.00K | 270.00K | 1.46M | 1.43M | -103.00K |
| Operating Expenses | 104.32M | 107.37M | 85.87M | 86.46M | 119.32M | 75.69M | 54.86M | 25.58M | 6.56M |
| Cost & Expenses | 104.32M | 107.37M | 85.87M | 86.46M | 119.32M | 75.69M | 54.86M | 25.58M | 6.56M |
| Interest Income | 7.14M | 2.62M | 64.00K | 115.00K | 1.58M | 619.00K | 219.00K | 369.00K | 3.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.58M | 2.41M | 2.96M | 3.92M | 2.82M | 1.57M | 448.00K | 56.00K | 6.56M |
| EBITDA | -93.43M | -96.87M | -69.29M | -84.37M | -116.49M | -75.69M | -54.41M | -25.52M | 119.00K |
| EBITDA Ratio | 0.00% | -1,333.38% | -508.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.32M | -106.45M | -72.25M | -88.41M | -119.32M | -75.69M | -54.86M | -25.58M | -6.56M |
| Operating Income Ratio | 0.00% | -1,315.20% | -530.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 20.47M | 66.00K | -1.83M | 2.10M | 889.00K | 1.68M | 1.80M | -100.00K |
| Income Before Tax | -96.02M | -85.98M | -72.19M | -88.29M | -117.22M | -74.80M | -53.18M | -23.77M | -6.66M |
| Income Before Tax Ratio | 0.00% | -1,062.28% | -530.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -20.47M | -64.00K | 1.83M | -1.58M | 889.00K | -1.28M | -2.60M | -287.00K |
| Net Income | -96.02M | -65.51M | -72.12M | -90.12M | -115.64M | -74.80M | -52.12M | -21.54M | -6.38M |
| Net Income Ratio | 0.00% | -809.36% | -529.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.83 | -7.70 | -10.13 | -26.03 | -43.05 | -33.73 | -24.26 | -16.80 | -4.97 |
| EPS Diluted | -4.83 | -7.70 | -10.13 | -26.03 | -43.05 | -33.73 | -24.26 | -16.80 | -4.97 |
| Weighted Avg Shares Out | 19.88M | 8.51M | 7.12M | 3.46M | 2.69M | 2.22M | 2.15M | 1.28M | 1.28M |
| Weighted Avg Shares Out (Dil) | 19.88M | 8.51M | 7.12M | 3.46M | 2.69M | 2.22M | 2.15M | 1.28M | 1.28M |
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
Solid Biosciences to Present at the Jefferies London Healthcare Conference
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel...
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 51,338 restricted stock units (“RSUs”) to three newly hired...
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 42,082 restricted stock units (“RSUs”) to three newly hired...
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 –
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units (“RSUs”) to four newly hired...
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.
Source: https://incomestatements.info
Category: Stock Reports